Study says double polio shot is best bet
Source: Agencies |
October 27, 2010, Wednesday
|
Print Edition
Print Edition
A NEW double-strain polio vaccine is more effective than triple and single vaccines and means children in high-risk areas can be immunized against two key strains of the crippling virus in a single dose, scientists say.
In a study in the Lancet journal yesterday, World Health Organization scientists said research on the bivalent oral polio vaccine, known as bOPV, found it induced a "significantly higher immune response" than triple vaccines.
Researcher Roland Sutter said the findings showed that the new oral vaccine, which is made for WHO vaccination programs by various drug firms, including Britain's GlaxoSmithKline and India's Panacea Biotec, would be a potent weapon in the battle to eradicate the crippling virus.
"The main advantage of the bivalent is that it is so effective against type 1 and type 3 poliovirus at the same time," he said. "The impact has been quite dramatic already in India and in Nigeria with cases coming down to very low levels this year."
Polio, which spreads in areas with poor sanitation, attacks the nervous system and can cause irreversible paralysis within hours of infection. Children under five are the most vulnerable.
In 1988, when the WHO and its partners formed the Global Polio Eradication Initiative to lead a drive to eradicate polio, the virus was endemic in 125 countries and paralyzed nearly 1,000 children every day.
Mass vaccination with older triple, or trivalent, oral polio vaccines have helped reduced the number of countries where polio is endemic to just four. But despite the use of these triple vaccines as well as monovalent, or single strain vaccines, polio virus types 1 and 3 are still circulating in the polio-endemic countries of Afghanistan, Pakistan, India and Nigeria.
In their study, conducted between August and December 2008, Sutter and colleagues analyzed data from 830 newborn babies from three centers in India who received either the monovalent, bivalent or trivalent vaccines in two doses, one at birth and one 30 days later.
Blood samples were taken before vaccination and after the first and second doses to measure rises in antibody levels and the researchers found that, in targeting polio types 1 and 3, bOPV was better than both the triple and single vaccines.
In a study in the Lancet journal yesterday, World Health Organization scientists said research on the bivalent oral polio vaccine, known as bOPV, found it induced a "significantly higher immune response" than triple vaccines.
Researcher Roland Sutter said the findings showed that the new oral vaccine, which is made for WHO vaccination programs by various drug firms, including Britain's GlaxoSmithKline and India's Panacea Biotec, would be a potent weapon in the battle to eradicate the crippling virus.
"The main advantage of the bivalent is that it is so effective against type 1 and type 3 poliovirus at the same time," he said. "The impact has been quite dramatic already in India and in Nigeria with cases coming down to very low levels this year."
Polio, which spreads in areas with poor sanitation, attacks the nervous system and can cause irreversible paralysis within hours of infection. Children under five are the most vulnerable.
In 1988, when the WHO and its partners formed the Global Polio Eradication Initiative to lead a drive to eradicate polio, the virus was endemic in 125 countries and paralyzed nearly 1,000 children every day.
Mass vaccination with older triple, or trivalent, oral polio vaccines have helped reduced the number of countries where polio is endemic to just four. But despite the use of these triple vaccines as well as monovalent, or single strain vaccines, polio virus types 1 and 3 are still circulating in the polio-endemic countries of Afghanistan, Pakistan, India and Nigeria.
In their study, conducted between August and December 2008, Sutter and colleagues analyzed data from 830 newborn babies from three centers in India who received either the monovalent, bivalent or trivalent vaccines in two doses, one at birth and one 30 days later.
Blood samples were taken before vaccination and after the first and second doses to measure rises in antibody levels and the researchers found that, in targeting polio types 1 and 3, bOPV was better than both the triple and single vaccines.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
